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In situ evaluation of podocin in normal and glomerular
diseases.
Background. Mutations of the NPHS2 gene are responsible
for autosomal-recessive steroid-resistant nephrotic syndrome.
Its product, podocin, faces the slit diaphragm area with its two
ends in the cytoplasm of foot processes.
Methods. We generated rabbit polyclonal antibodies against
conjugated peptides from human podocin N- and C-termini,
and studied podocin and synaptopodin using kidney tissues of
normal humans and those with glomerular diseases.
Results. Antipodocin antibodies detected the original 42 kD
fragment and an extra smaller fragment by Western blot anal-
ysis using human isolated mature glomeruli. RNA analysis
showed two bands, the original and the other of a decreased
length. Immunohistochemically, podocin was detected in a lin-
ear pattern along the glomerular capillary loop. Antipodocin
antibody (C-terminal) stained the smooth muscles of renal
arterioles and aorta. Among 42 patients, podocin was normally
expressed in glomeruli in purpura nephritis, IgA nephropa-
thy (IgAN), and minimal-change disease (MCD), while it was
either decreased or absent in most subjects with focal segmen-
tal glomerulosclerosis (FSGS). The expression of synaptopodin
was similar to that of podocin, although some discrepancy
existed.
Conclusion. Although indirect, our data suggest the existence
of a vascular isoform of podocin with a different molecular mass.
We propose that examination of podocin expression may help
differentiate MCD from FSGS.
Plasma ultrafiltration during primary urine formation
in the glomerulus is a central function of the kidney.
The glomerular barrier is comprised of a fenestrated en-
dothelium, glomerular basement membrane (GBM), and
highly specialized visceral epithelial podocytes, the foot
processes that cover the outer surface of the GBM. Dys-
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function of the glomerular filter causes proteinuria and
nephrotic syndrome ensues.
Several genes expressed by glomerular podocytes have
been identified [1–3]. Nephrin, a major component of
the slit diaphragm, is a transmembrane protein encoded
by the NPHS1 gene, which is mutated in congenital
nephrotic syndrome of the Finnish type [1]. Glomerular
expression of nephrin has been noted in kidney diseases
in humans [4, 5]. Targeted deletion of CD2-associated
protein (CD2AP) in mice developed nephrotic syn-
drome [6]. The NPHS2 gene encodes podocin, another
podocyte protein [2]. Mutations of NPHS2 are associated
with autosomal-recessive steroid-resistant nephrotic syn-
drome, which is characterized by early childhood onset of
proteinuria, focal segmental glomerulosclerosis (FSGS),
and rapid progression to end-stage renal disease (ESRD).
Podocin is structurally similar to stomatins and is pre-
dicted to be an integral membrane protein of 383 amino
acids. It has a single membrane domain forming a hairpin-
like structure and with both N- and C-terminal domains
in the cytosol [2, 7]. Podocin supposedly interacts with
nephrin and CD2AP [8, 9]. This complex is a functional
unit that anchors the slit diaphragm to the actin cytoskele-
ton and establishes its location in the lateral plasma
membrane of the podocyte foot processes. It plays an
important role in the molecular structure of the slit
diaphragm and filtration barrier.
Synaptopodin is an actin-associated protein of
podocyte and dendric spines in a subpopulation of exclu-
sively telencephalic synapses. Synaptopodin was found to
be associated with the actin microfilaments of podocyte
foot processes and may be associated with remodeling of
cell processes in the kidney [10].
Nephrotic syndrome can be caused by several glomeru-
lar diseases. Podocin is expressed in normal glomerular
podocytes [7], but its expression in glomerular diseases
is unknown. We generated rabbit antipodocin antibodies
and studied the expression of podocin and synaptopodin
in kidney tissues from normal subjects and those with
glomerular diseases.
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Table 1. Samples included in this study and clinical parameters at the time of biopsy
Samples number
Age years Gender Urinary protein g/day Serum creatinine Immunosuppressive
Diagnosis Total <20 >20 Male Female <0.3 0.3–1.0 >1.0 Hematuriaa Normal Elevated therapy
HSPN 6 6 0 3 3 1 1 4 6 6 0 4
IgAN 6 6 0 4 2 2 3 1 5 5 1 0
MCD 6 3 3 3 3 1 1 4 0 6 0 4
MN 5 0 5 3 2 0 0 5 5 5 0 0
FSGS 19 4 15 11 8 0 1 18 2 12 7 6
Total 42 19 23 24 18 4 6 32 18 34 8 14
Abbreviations are: HSPN, Henoch-Scho¨nlein purpura nephritis; IgAN, IgA nephropathy; MCD, minimal-change disease; MN, membranous nephropathy; FSGS,
focal segmental glomerulosclerosis.
aMore than five erythrocytes per high-power field.
METHODS
Patients
This study included 42 Japanese patients treated in
the Department of Pediatrics and Third Department
of Internal Medicine, Kumamoto University School
of Medicine, and Department of Pediatrics and De-
partment of Nephrology, Kumamoto Central Hospital
(24 men and 18 women; 19 patients <20 years of age).
Glomerular diseases included Henoch-Scho¨nlein pur-
pura nephritis (HSPN) (N = 6), IgA nephropathy (IgAN)
(N = 6), minimal-change disease (MCD) (N = 6), mem-
branous nephropathy (MN) (N = 5), and FSGS (N = 19)
(Table 1). Patients with MN were in stage 1 (N = 1), stage
2 (N =3), and stage 3 (N = 1). Renal tissue samples were
obtained by percutaneous needle or by open biopsies.
Diagnoses were established based on clinical symp-
toms, laboratory investigations, and kidney histopathol-
ogy. Kidney biopsy specimens were examined under a
light, an electron. and a fluorescent microscope. Data
on proteinuria, hematuria, serum creatinine, and albu-
min were collected at the time of renal biopsy. Protein-
uria was divided into three grades (<0.3 g/day, 0.3 to
1.0 g/day, and >1.0 g/day). Hematuria was defined as
more than five erythrocytes per high-power field. Thirty-
two patients had severe proteinuria (>1.0 g/day) and
six had moderate proteinuria (0.3 to 1.0 g/day) at the
time of biopsy. Eighteen patients were hematuric. Eight
patients had elevated serum creatinine levels and 14 had
been treated with steroids or other immunosuppressive
therapy prior to renal biopsy.
We obtained informed consent from patients or their
family members for analyzing podocin expression.
Antipeptide antibody
Oligopeptides (MERRARSSSRESRGR) corre-
sponding to amino acid residues 1-15 (N-terminal) and
(SKPVEPLNPKKKDS) to amino acid residues 367-380
(C-terminal) of human podocin were synthesized [2].
Neither N- nor C-terminal fragments of podocin had
any homology with known protein sequences [2]. The
peptides were conjugated with keyhole limpet hemo-
cyanin (KLH). Rabbits were immunized with conjugated
peptides four times every 2 weeks. For Western blot
and immunohistochemical analyses, antisera were puri-
fied on immunoaffinity columns coupled with peptides
used for immunization.
Western blot analysis
Normal adult human kidney samples were obtained
from patients with renal cancer who underwent nephrec-
tomy. Glomeruli were isolated by sieving, as described
elsewhere [11]. Proteins were extracted from isolated
glomeruli into lysis buffer [0.05 mol/L sodium phos-
phate/0.15 mol/L NaCl/1% Triton X-100/0.1 mmol/L
phenylmethylsulphate/10 mmol/L ethylenediaminete-
traacetic acid (EDTA), pH 7.5]. After vortexing, protein
samples were incubated on ice for 30 minutes, then
centrifuged to clear the supernatant. The lysates were
diluted in Laemmli sample buffer in the presence or ab-
sence of 5% 2-mercaptoethanol and subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). The separated proteins were transferred
electrophoretically onto a polyvinylidene difluoride
transfer membrane (Millipore, Bedford, MA, USA).
The membrane was treated with 5% dry fat milk for
blocking, and then treated with diluted antipodocin
antisera (1:100) or normal rabbit IgG (1:100). Primary
antibodies were detected using horseradish peroxidase-
conjugated antirabbit IgG (Rockland, Gilbertsville, PA,
USA) as the secondary antibody. Signals were detected
using a chemiluminescent reagent ECL Plus System
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
RNA analysis
Total RNA was extracted from normal adult hu-
man whole kidney using an acid guanidinium thio-
cyanate/phenol/chloroform extraction procedure [12].
First-strand cDNA was generated from total RNA and
was reverse transcribed using an RNA polymerase chain
reaction (PCR) kit (Takara, Otsu, Japan). The NPHS2
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gene has eight exons. cDNA was amplified with an LA
PCR kit (Takara) with NPHS2 primers 1A and 8B.
Sequences of oligonucleotide primers were as follows
[2]: 1A, 5′-GCAGCGACTCCACAGGGACT-3′ (exon 1,
sense); 8B, 5′-TTCTATGGCAGGCCCCTTTA-3′ (exon
8, antisense). The amplified DNAs were electrophoresed
on a 1.5% agarose gel.
Immunohistochemistry in glomeruli
Immunohistochemical analysis was done for human
normal mature kidney and 42 patients’ kidneys. For
immunostaining, serial sections (4 lm) were fixed in
acetone for 10 minutes at room temperature then incu-
bated in 5% goat serum for 30 minutes at room tem-
perature to block nonspecific binding. The sections were
then incubated overnight at 4◦C with affinity-purified
antipodocin antibody (Podo-N) (1:100), or antisynap-
topodin antibody (1:100). We used a mouse mono-
clonal antisynaptopodin antibody (Progen, Heidelberg,
Germany). Thereafter, primary antibodies were detected
using fluorescein isothiocyanate (FITC)-conjugated goat
antirabbit IgG (ICN Pharmaceuticals, Inc., Aurora, OH,
USA) or FITC-conjugated rabbit antimouse IgG (MBL)
as secondary antibodies, respectively. Sections were ex-
amined under a fluorescent microscope. The expression
of podocin was recorded by two independent observers
using an arbitrary scale of (−), negative; (+), faintly pos-
itive; (2+), positive; and (3+), strongly positive.
To check the condition of normal kidney samples, we
repeatedly froze and thawed samples ten times. Podocin
was normally detected after ten times of freezing and
thawing, while signals of synaptopodin decreased when
the repetition exceeded five times. Therefore, we used
samples subjected to less than five times of freezing and
thawing.
For dual fluorochrome labeling, sample slides were
simultaneously incubated overnight at 4◦C with rabbit
antipodocin antibody, mouse antisynaptopodin or rat
anti-a5 chain of type IV collagen [a5(IV) chain] antibody.
After washing with phosphate-buffered saline (PBS), the
slides were simultaneously incubated with rhodamine-
conjugated goat antirabbit IgG, FITC-conjugated rabbit
antimouse IgG or FITC-conjugated goat antirat IgG, re-
spectively, as secondary antibodies for 1 hour at room
temperature. Sections were examined under fluorescent
and confocal microscopes (Fluoview FV-500, Olympus,
Tokyo, Japan).
To ascertain the presence of renal glomerular blood
vessels in patients, we studied dual fluorochrome label-
ing of podocin and ZO-1, a component of cytoplasmic
face of the slit diaphragm. Sample slides were stained
as above with Podo-N antibody or mouse anti-ZO-1
antibody (Zymed, South San Francisco, CA, USA) as
primary antibodies, and with FITC-conjugated goat an-
tirabbit IgG or rhodamine-conjugated goat antimouse
IgG, respectively, as secondary antibodies.
Immunohistochemistry in extraglomeruli
We studied dual fluorochrome labeling of smooth mus-
cle actin (SMA) and podocin in human renal arterioles.
Sample slides were stained as above with mouse anti-
SMA antibody or Podo-C antibody as primary antibod-
ies, and with FITC-conjugated rabbit antimouse IgG or
rhodamine-conjugated goat antirabbit IgG, respectively,
as secondary antibodies.
Immunohistochemical analysis was done for human
normal mature kidney and aorta using serial paraffin sec-
tions to exclude the possibility of autoimmunofluores-
cence of the vascular elastic laminas. The sections were
incubated with 0.1% trypsin at 37◦C for 30 minutes, then
incubated in 5% goat serum for 30 minutes at room tem-
perature to block nonspecific binding. They were incu-
bated overnight at 4◦C with Podo-C antibody (1:10) as
a primary antibody and peroxidase-conjugated goat an-
tirabbit IgG (ICN Pharmaceuticals, Inc.) as a secondary
antibody. Sections were stained with diaminobenzidine
(DAB) substrate kit with nickel (Vector Laboratories,
Inc., Burlingame, CA, USA), then examined under a light
microscope.
RESULTS
Characterization of polyclonal antipodocin antibodies
Polyclonal rabbit antisera were raised against con-
jugated proteins derived from two regions of human
podocin and then purified by immunoaffinity columns.
Podo-N and Podo-C were N- and C-terminal antibodies,
respectively. The Podo-N antibody did not react with a
nonassociated peptide but was reactive with an oligopep-
tide of the N-terminal of podocin, and antibodies against
the bridge region, including KLH, were removed by an
immunoaffinity column (Fig. 1A). Likewise the Podo-C
antibody reacted with an oligopeptide of the C-terminal
of podocin (data not shown). The specificity of these an-
tibodies was tested by Western blot analysis with pro-
tein derived from mature isolated glomeruli from humans
(Fig. 1B). Both Podo-N and Podo-C antibodies recog-
nized the original 42 kD band and the extra 32 kD band,
while these bands were not detected by normal rabbit
IgG (Fig. 1B). This result was confirmed by other inde-
pendent Western blots using five normal controls. The
42 kD fragment is estimated to be intact podocin [7].
RNA analysis
Reverse transcription (RT)-PCR using total RNA
from normal adult human kidney with primers 1A and
8B showed an original length (1275 bp) and another de-
creased length of approximately 200 bp in NPHS2 mRNA
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Fig. 1. (A) Reactivity of a rabbit polyclonal
antibody directed against the N-terminal
region of podocin (Podo-N) with three
peptides by enzyme-linked immunosorbent
assay (ELISA). Symbols are () oligopep-
tide (N-terminal); (), keyhole limpet
hemocyanin (KLH)-conjugated oligopep-
tide (N-terminal); (), KLH-conjugated
nonassociated peptide. Absorbance at
490 nm. The concentration of Podo-N
antibody is indicated by ng/mL. The Podo-N
antibody did not react with a nonassociated
peptide but was reactive with the oligopeptide
of the N-terminal of podocin, and antibodies
against the bridge region, including KLH,
were removed by an immunoaffinity column.
(B) Western blot analysis of normal human
glomerular extract using Podo-N (lane 1)
and Podo-C (C-terminal region) (lane 2)
antibodies. Bands at 42 kD and 32 kD can
be seen by both antipodocin antibodies. The
protein of 42 kD fragment was estimated
to be intact podocin. Normal rabbit IgG
(lane 3) did not show any immunoreactivity.
(C) Reverse transcription-polymerase chain
reaction (RT-PCR) using total RNA from
normal adult human kidney with NPHS2
primers 1A and 8B, and electrophoresis on
a 1.5% agarose gel. Lane 1 is 1 kb marker.
RT-PCR showed an original length (1275 bp)
and a decreased length of approximately
200 bp in NPHS2 mRNA, indicated by
arrowheads (lane 2).
(Fig. 1C). This result indicates that NPHS2 mRNA is
alternatively spliced and supports the Western blot anal-
ysis above.
Podocin expression in normal glomeruli
In immunofluorescent staining of normal mature
glomeruli, a similar staining pattern was observed with
the two antipodocin antibodies (Fig. 2A and B) but
with no staining with normal rabbit IgG (Fig. 2C). Poly-
clonal antibodies Podo-N and Podo-C gave a linear label-
ing along the GBM, somewhat granular as described by
Roselli et al [7].
To examine the subcellular localization of podocin,
double immunofluorescent labeling was performed on
human mature glomeruli, using the Podo-N antibody
(in red) and antibodies directed against synaptopodin (in
green) and the a5(IV) chain (in green) (Fig. 2D to J). Dual
labeling with podocin and synaptopodin showed a tight
colocalization of both markers as evidenced by yellow la-
beling outlining the GBM (Fig. 2D to F). The anti-a5(IV)
chain antibody gave a strong linear labeling of the GBM.
Dual stained sections seen at low magnification showed a
nearly complete colocalization of red and green labeling
(Fig. 2G to I). However, high magnification and confocal
microscopy examination disclosed a distinct green linear
labeling of the GBM with the anti-a5(IV) chain antibody
from the red labeling of the base of the podocytes with
the anti-podocin antibody (Fig. 2J).
Podocin expression in normal extraglomeruli
The Podo-N antibody stained glomeruli only, while the
Podo-C antibody stained renal arteriole walls as well as
glomeruli (Fig. 3A). Double immunofluorescent labeling
of human mature kidneys using Podo-C and anti-SMA
antibodies showed that a protein with the C-terminal
region of podocin colocalized with the smooth muscles of
renal arteriole walls (Fig. 3A to C). To exclude the possi-
bility of autofluorescence of the vascular elastic laminas,
we examined renal arteriole and aorta by immunoperox-
idase staining. The Podo-C antibody stained not only the
smooth muscle of renal arteriole (Fig. 3D), but also that
of aorta (Fig. 3E). Tubuli and Bowman’s capsules were
not stained.
Podocin expression in glomerular diseases
The Podo-N antibody was used for immunohistochem-
istry studies as below. Podocin was normally detected
in all patients with HSPN, IgAN and MCD (Fig. 4A,
C, and E). Although podocin expression in MCD may
appear high in the figure, the degree of immunostain-
ing in MCD was in fact the same as that in HSPN and
IgAN through a microscope. In 19 patients with FSGS, the
expression of podocin was either decreased (1+) (7/19)
or completely absent (−) (7/19) (Fig. 4I), and in only five
patients was it present by more than 2+ (Tables 2 and
3). In FSGS, podocin was absent in the sclerotic regions.
2096 Horinouchi et al: Evaluation of podocin in glomerular diseases
Fig. 2. Immunohistochemistry of podocin in normal human mature
glomeruli. Immunostaining of podocin using anti-N-terminal region of
podocin (Podo-N) (A) and anti-C-terminal region of podocin (Podo-C)
(B) antibodies and using normal rabbit IgG (C). Podo-N and Podo-
C gave the linear labeling along the glomerular basement membrane
(GBM) (A and B), with no staining with normal rabbit IgG (C). Dual im-
munofluorescence with Podo-N (red) (D and G) and antibodies (green)
against synaptopodin (E) or the a5 chain of type IV collagen (a5(IV)
chain) (H), and merge (yellow) (F and I) in a human mature kidney.
The red podocin labeling of podocytes is colocalized with synaptopodin
labeling (F), and appears to be colocalized with the a5(IV) chain at low
magnification (I), but follows the external aspect of the a5(IV) chain of
the green GBM with high magnification and a confocal microscope (J).
Tubuli and Bowman’s capsule were not stained (A to I ×500, J ×1400).
In some cases, the staining pattern of podocin changed
from linear to segmental. The reduction or absence in
staining of podocin was seen in all examined glomeruli in
patients with FSGS. In four of five patients with MN, it
was present by more than 2+ (Fig. 4G). One case of MN
with a decrease (1+) in signal of podocin was in stage 2.
Synaptopodin signals were similar to podocins (Fig. 4B,
D, F, H, and J). In 11 of 19 patients with FSGS, synap-
topodin was absent (Fig. 4J) (Tables 2 and 3), while in
MCD it was normally present (Fig. 4F). Fibrous area
could not be stained with either antipodocin or antisynap-
topodin antibodies. There was some discrepancy between
staining levels of podocin and synaptopodin in patients
with FSGS (Table 3). In FSGS, both expression patterns
were similar in glomeruli, and we could not point out any
difference in staining areas.
Signals of ZO-1 were stable in all of these glomeruli
(Fig. 4K), even when staining of podocin was absent or
reduced in the three nephrotic diseases. We can therefore
conclude that the tissue was not damaged and capillary
loop was present.
Podocin expression and clinical parameters
We examined the correlation of podocin expression
with clinical parameters in 19 patients with FSGS. We
compared seven patients with no podocin expression
with five patients who had podocin expression of more
than 2+. Proteinuria was 4.7 +/− 3.4 g/day (mean +/−
SD) vs. 3.6 +/− 0.5 g/day, serum creatinine was 2.6 +/−
3.6 mg/dL vs. 0.7 +/− 0.1 mg/dL, serum albumin was
3.0 +/− 0.9 g/dL vs. 2.7 +/− 0.9 g/dL, respectively. There
was no statistical significance between podocin expres-
sion and the three clinical parameters in patients with
FSGS.
DISCUSSION
We generated two antipodocin antibodies. Both anti-
bodies detected the same original band of 42 kD frag-
ment, which is consistent with the molecular weight of
podocin [2]. Roselli et al [7] also generated rabbit an-
tipodocin polyclonal antibodies, which detected a single
band of 49 kD by Western blot analysis. They used trans-
fected HEK293 cell lysates as a protein for Western blot
analysis, while we used a protein derived from human
isolated mature glomeruli. The mouse and rat podocin
has been recently identified and is predicted to be a pro-
tein of 385 and 383 amino acids, respectively [13, 14].
The amino acids sequences of murine podocin show more
than 80% identity to human podocin. Molecular weight of
both murine podocins are 42 kD by Western blot analysis
using normal murine isolated glomeruli [13–15]. The dif-
ference in band size of human podocin may be caused by
the nature of the original cells used, or be related to post-
translational modifications. Furthermore, immunoblot
analysis showed that both our antibodies recognized an
extra band of 32 kD fragment in mature glomeruli. This
result was confirmed by other independent Western blot
analyses using five normal controls. Forty to sixty per-
cent of human genes have alternative splice forms [16].
RT-PCR using RNA from human mature kidney showed
two bands, one with an original length and the other with
a decreased length of approximately 200 bp in NPHS2
cDNA. RT-PCR with other primers amplifying exons
2 to 8 showed two bands, one with a putative length
and the other with a decreased length of approximately
200 bp (data not shown). The deletion may be between
exons 3 and 7. Strausberg reported a clone similar to
the NPHS2 gene. This clone deletes exon 5 (204 bp)
in-frame and encodes a smaller podocin of 315 amino
acids including both the N- and C- termini of podocin
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Fig. 3. Podocin expression in the normal extraglomeruli. Dual im-
munofluorescence with anti-C-terminal region of podocin (Podo-C) an-
tibody (red) (A) and antismooth muscle actin (SMA) antibody (green)
(B), and merge (yellow) (C) in normal human mature kidney. A Podo-
C antibody stained renal arteriole. Podocin colocalized with smooth
muscle of renal arteriole walls (A to C). Immunoperoxidase staining
showed that Podo-C antibody stained not only smooth muscle of renal
arteriole (D), but also that of aorta (E). Tubuli and Bowman’s capsules
were not stained (A to E ×500).
Table 2. Expression of podocin and synaptopodin in glomerular
diseases
Degree of expression Degree of expression
of podocin of synaptopodinSamples
Diagnosis number 3+ 2+ 1+ — 3+ 2+ 1+ —
HSPN 6 6 4 2
IgAN 6 6 5 1
MCD 6 6 5 1
MN 5 3 1 1 3 1 1
FSGS 19 1 4 7 7 4 2 2 11
Total 42 22 5 8 7 21 5 5 11
Abbreviations are: HSPN, Henoch-Scho¨nlein purpura nephritis; IgAN, IgA
nephropathy; MCD, minimal-change disease; MN, membranous nephropathy;
FSGS, focal segmental glomerulosclerosis.
(GenBank accession # BC029141). The smaller podocin
in the present study may be derived from an alternatively
spliced mRNA of podocin.
In glomeruli, both antipodocin antibodies Podo-N and
Podo-C showed the same staining patterns as reported
[7]. The Podo-C antibody did stain the smooth muscles in
renal arteriole and aortic walls, while Podo-N antibody
did not. Since vascular elastic laminas have a green
autofluorescence, we confirmed it by immunoperoxidase
staining. Although indirect, our data suggest the exis-
tence of a vascular isoform of podocin with a different
molecular mass. We thought of two possibilities to
explain how an isoform of podocin may lose antigenecity
for the Podo-N antibody in the vessels immunohisto-
chemically and still be reserved by immunoblot analysis.
First, proteins change structure to a straight form in West-
ern blot analysis, while in tissue the area that the Podo-N
antibody recognizes maintains a three-dimensional
structure. This may lead to a loss in antigenecity in tissue.
Fig. 4. Immunofluorescent study for podocin (A, C, E, G, and I), synap-
topodin (B, D, F, H, and J) and ZO-1 (K) in biopsy samples of glomerular
diseases which are comprised of Henoch-Scho¨nlein purpura nephritis
(HSPN) (A and B), IgA nephropathy (IgAN) (C and D), minimal-
change disease (MCD) (E and F), membranous nephropathy (MN)
(G and H), and focal segmental glomerulosclerosis (FSGS) (I to K).
Podocin was normally present in all patients with HSPN, IgAN, and
MCD (A, C, and E). In contrast, podocin expression decreased or was
absent in fourteen of 19 patients with FSGS (I). In four of five patients
with MN, podocin was normal (G). In some cases, podocin changed
from a linear to a segmental pattern. The signal of synaptopodin was
similar to that of podocin (B, D, F, H, and J). In eleven of 19 patients with
FSGS, the expression of synaptopodin was absent (J), while in MCD
it was normally present (F). The signal of ZO-1 was stable in patients
with FSGS (K) (A to K ×500).
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Table 3. Clinical course of patients with minimal-change disease (MCD) and focal segmental glomerulosclerosis (FSGS)
Serum Urine
Stainingc TreatmentdAgea Creatinine Albumin Protein
Cases years Genderb PN Sy mg/dL mg/dL g/day Hematuria Prebiopsy Postbiopsy Prognosise
MCD
1 3 M 3+ 3+ 0.3 3.5 1.3 − PSL PSL CR
2 10 F 3+ 3+ 0.5 3.8 0.03 − PSL PSL CR
3 18 M 3+ 3+ 0.8 1.6 7.6 − PSL+CsA PSL CR
4 21 M 3+ 2+ 0.7 1.3 5.0 − PSL PSL CR
5 39 F 3+ 3+ 0.6 2.5 2.1 − — PSL CR
6 59 F 3+ 3+ 0.5 3.4 0.7 − — — CR
FSGS
1 19 M 3+ 3+ 0.8 3.5 3.4 − Steroid-pulse, HD PSL + CsA Relapse, CR
2 16 F 2+ 3+ 0.5 1.6 3.6 − — PSL + CsA CR
3 30 M 2+ 1+ 0.8 3.0 4.4 − — PSL IR
4 37 F 2+ — 0.7 3.6 3.0 − Steroid-pulse — IR
5 63 F 2+ 3+ 0.7 1.9 3.7 − — PSL + CsA CR
6 2 M 1+ — 0.3 3.2 0.3 + PSL PSL + CsA IR
7 29 M 1+ 3+ 1.2 1.6 9.0 − PSL PSL + LDL IR
apheresis
8 32 F 1+ 1+ 0.7 4.6 1.6 − — — Denial of
treatment
9 43 F 1+ 2+ 0.7 2.4 6.8 − — PSL + CsA CR
10 55 M 1+ — 1.1 3.8 2.5 − — — CR
11 61 F 1+ 2+ 4.4 1.6 12.0 + — PSL + CsA CR
12 71 F 1+ — 0.7 2.0 7.0 − — LDL apheresis CR
13 6 M — — 0.8 2.6 6.2 − PSL PSL ESRD
(CAPD/HD)
14 6 M — — 0.6 3.7 1.8 − PSL PSL ESRD
(CAPD/HD)
15 44 M — — 1.9 3.8 2.5 − — PSL + CsA IR
16 51 M — — 11.0 3.4 3.0 − — PSL + CsA Denial of HD, IR
17 56 M — — 1.0 4.0 2.5 − — PSL IR
18 59 F — — 0.6 1.8 12.0 − — PSL + CsA CR
19 66 M — — 2.4 1.8 5.5 − — PSL + CsA Relapse, CR
aAge at biopsy; bF, female; M, Male; cPN, staining of podocin-N; Sy, staining of synaptopodin; dPSL, prednisolone; CsA, cyclosporin; eCR, complete remission; IR,
incomplete remission; ESRD, end-stage renal disease; CAPD: continuous ambulatory peritoneal dialysis; HD, hemodialysis.
Second, the deletion of NPHS2 exon 5 may change
the structure of podocin, so that the Podo-N antibody
would not stain immunohistochemically. The mRNA of
rat podocin is expressed not only in podocytes but also in
nerve tissues such as the cerebrum, cerebellum, and the
medulla oblongata [13]. Rat podocin is localized in the
outer area of astrocyte-facing vessels. Podocin may play
an important role in the vessels such as renal arteriole
and aortic walls as well as maintain the barrier function
in the glomerular capillary wall and blood-brain barrier
[13].
The expression of nephrin has been reported contro-
versially in proteinuric diseases [17–19]. This is the first
report of podocin expression in human glomerular dis-
eases, especially in nephrotic syndrome such as MCD,
FSGS and MN. The amount of podocin did not de-
crease in any of the six patients with MCD. Four of them
were treated with immunosuppressive therapy (Table 3).
One was in partial remission, three had proteinuria, and
two were nephrotic at the time of renal biopsy. Podocin
expression in MCD seems to be maintained whether a
patient is in an active or a remission phase, and whether
treated or not. In MCD, five patients responded to steroid
and one patient received no therapy; all are currently
in complete remission. In contrast, podocin expression
seems to be either decreased or absent in 74% cases of
FSGS. Examination of podocin expression will be useful
to differentiate MCD from FSGS.
In FSGS, cases with sufficient podocin expression
tended to have good prognosis. Case 1 of FSGS, whose
podocin was normally expressed, experienced some re-
lapse, but responded to steroid and is now in complete
remission. On the other hand, of the seven FSGS pa-
tients with no podocin expression, two (29%) progressed
to ESRD (Table 3), indicating possible poor prognosis.
Cases 13 and 14 of FSGS had steroid-resistant nephrotic
syndrome at an infant stage, and dialysis was introduced.
Case 13 had a familial history. After obtaining informed
consent for gene analysis in the case 13 from his par-
ents, we analyzed the NPHS2 gene, but did not find any
mutation. There are several causes of FSGS. Although
it is not clear what the variation of podocin expression
means, our view is that a decrease or absence of podocin
means damage of the filtration barrier either primarily or
secondarily, and possible resistance to immunosuppres-
sive therapy.
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In MN, podocin was normal in most cases, and there
was no correlation between the staining pattern of
podocin and the stage of the disease.
Podocin was normally present in HSPN and IgAN. The
principal region responsible for the two diseases is not
the slit diaphragm but the mesangial region. Therefore,
podocin would not be primarily involved in these dis-
eases. Amounts of podocin detected by immunochem-
istry are likely to be as follows: HSPN, IgAN, MCD >
MN > FSGS, although further examination is needed in
many more cases with glomerular diseases.
We compared the expression of podocin with synap-
topodin in glomerular diseases. Their stainings of
them were similar, although some discrepancy existed
(Table 3). Synaptopodin is not only a marker of the
podocyte but also a marker of the differentiation of the
podocyte [20]. Reduction or absence of podocin and
synaptopodin stainings should mean injury of podocyte
structure and/or function.
We examined the correlation of podocin expression
with clinical parameters in patients with FSGS, but there
was no significance, which may be due to the small
number of patients. In this study, the expression of
podocin was examined only once in each individual case.
It would be ideal to examine chronological changes of
podocin and clinical parameters in cases of repeated
biopsies.
CONCLUSION
Although indirect, our data suggest the existence of
a vascular isoform of podocin with a different molec-
ular mass. This isoform may play an important role in
the vessels. Podocin was normally present in glomeruli in
HSPN, IgAN, MCD, and most cases of MN, while it was
either decreased or absent in most cases (74%) of FSGS.
Podocin in MCD is maintained even in an active phase.
Examination of podocin expression should be useful to
differentiate MCD from FSGS.
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